G0S2 and chronic myelogenous leukemia, BCR-ABL1 positive: Altogether, our findings suggest that loss of G0S2 occurs in multiple contexts of TKI resistance and progression in CML, and that restoring G0S2 expression in such scenarios may have clinical utility by promoting myeloid differentiation and restoring TKI sensitivity.